

Giorgio G Fumagalli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7509969/publications.pdf>

Version: 2024-02-01

90
papers

3,340
citations

185998

28
h-index

161609

54
g-index

91
all docs

91
docs citations

91
times ranked

4853
citing authors

#	ARTICLE	IF	CITATIONS
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	0.7	18
2	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	3.7	27
3	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum τ NfL and τ pNfH: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	2.8	21
4	Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1045-1052.	1.2	7
5	Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 431-442.	1.2	2
6	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	3.0	4
7	Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1009-1020.	1.2	5
8	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	1.1	2
9	Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 33.	3.0	9
10	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.4	24
11	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	1.5	1
12	The τ CBI τ detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	1.7	1
13	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.4	36
14	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12185.	1.2	11
15	Facing the digital divide into a dementia clinic during COVID-19 pandemic: caregiver age matters. <i>Neurological Sciences</i> , 2021, 42, 1247-1251.	0.9	47
16	Detection of the SQSTM1 Mutation in a Patient with Early-Onset Hippocampal Amnesic Syndrome. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 477-481.	1.2	2
17	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	2.8	42
18	Diogenes syndrome in dementia: a case report. <i>BJPsych Open</i> , 2021, 7, e43.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Analysis of C9orf72 Intermediate Alleles in a Retrospective Cohort of Neurological Patients: Risk Factors for Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1445-1451.	1.2	6
20	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	3.0	12
21	Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1313-1323.	1.2	5
22	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	1.4	28
23	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	1.4	8
24	Unravelling the association between amyloid-pet and CSF biomarkers: Who really deserves an A β +?. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117853.	0.3	0
25	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	4.4	9
26	Low CSF β -amyloid levels predict early regional grey matter atrophy in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101899.	0.9	5
27	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	4.9	175
28	Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102453.	1.4	11
29	Phenotypic heterogeneity of the rare R377W PSEN1 mutation: Late-onset presentation with mixed Alzheimer's and frontotemporal dementia features. <i>Alzheimer's and Dementia</i> , 2020, 16, e042581.	0.4	0
30	Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1268-1269.	1.4	35
31	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer's Disease. <i>Cells</i> , 2020, 9, 1443.	1.8	60
32	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. <i>Neurological Sciences</i> , 2020, 41, 3175-3183.	0.9	16
33	Crossing Borders Between Frontotemporal Dementia and Psychiatric Disorders: An Updated Overview. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 661-673.	1.2	3
34	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	2.8	19
35	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	1.1	26
36	CSF β -amyloid predicts prognosis in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1223-1231.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 84.	3.0	28
38	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	4.9	128
39	Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1173-1179.	1.2	4
40	Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease. <i>Cytokine</i> , 2019, 116, 115-119.	1.4	6
41	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	2.1	33
42	Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 663-669.	1.2	21
43	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2019, 142, 1108-1120.	3.7	41
44	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	1.4	27
45	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. <i>NeuroImage</i> , 2019, 188, 282-290.	2.1	16
46	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	1.5	47
47	Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β -amyloid levels and brain volumes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 280-287.	3.3	28
48	The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 31-38.	1.4	39
49	Drug Prescription and Delirium in Older Inpatients. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	16
50	Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1289-1294.	1.2	2
51	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
52	Diagnosis of Frontotemporal Dementia. , 2018, , 113-121.		0
53	Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 131-140.	1.9	41
54	CSF β -amyloid and white matter damage: a new perspective on Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 352-357.	0.9	36

#	ARTICLE	IF	CITATIONS
55	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 191-196.	1.5	151
56	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 245.e9-245.e12.	1.5	40
57	Behavioral and Neurophysiological Effects of Transcranial Direct Current Stimulation (tDCS) in Fronto-Temporal Dementia. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 235.	1.0	19
58	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. <i>Nature Communications</i> , 2018, 9, 4273.	5.8	263
59	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 46.	3.0	34
60	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1025-1036.	1.7	39
61	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2017, 140, 1784-1791.	3.7	55
62	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. <i>NeuroImage: Clinical</i> , 2017, 15, 171-180.	1.4	63
63	Evidence of CNS β -amyloid deposition in Nasu-Hakola disease due to the TREM2 Q33X mutation. <i>Neurology</i> , 2017, 89, 2503-2505.	1.5	26
64	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 47-52.	1.2	8
65	CSF β -amyloid as a putative biomarker of disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1085-1091.	1.4	33
66	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. <i>Neurological Sciences</i> , 2017, 38, 83-91.	0.9	11
67	Alzheimer's Disease Diagnosis: Discrepancy between Clinical, Neuroimaging, and Cerebrospinal Fluid Biomarkers Criteria in an Italian Cohort of Geriatric Outpatients: A Retrospective Cross-sectional Study. <i>Frontiers in Medicine</i> , 2017, 4, 203.	1.2	8
68	PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 353-357.	1.2	15
69	P1025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI). <i>Alzheimer's and Dementia</i> , 2016, 12, P409.	0.4	0
70	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016, 139, 1211-1225.	3.7	174
71	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P289-P289.		0
72	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. <i>Lancet Neurology</i> , The, 2015, 14, 253-262.	4.9	432

#	ARTICLE	IF	CITATIONS
73	Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. <i>Brain, Behavior, and Immunity</i> , 2015, 49, 182-187.	2.0	51
74	Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations. <i>International Journal of Molecular Sciences</i> , 2015, 16, 1385-1394.	1.8	14
75	Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. <i>PLoS ONE</i> , 2015, 10, e0140639.	1.1	4
76	Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. <i>Immunotherapy</i> , 2014, 6, 23-28.	1.0	3
77	Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1261-1267.	1.2	188
78	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. <i>Biological Psychiatry</i> , 2013, 74, 384-391.	0.7	105
79	A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val <i><i>EIF2B3</i></i> mutation. <i>Neurology</i> , 2012, 79, 2077-2078.	1.5	16
80	Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 447-452.	1.2	60
81	Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. <i>Journal of Neurology</i> , 2012, 259, 1470-1471.	1.8	12
82	BAG1 is a Protective Factor for Sporadic Frontotemporal Lobar Degeneration but not for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 701-707.	1.2	12
83	Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 253-259.	1.2	62
84	A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 19-26.	1.2	28
85	Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimer's disease. <i>Journal of Neurology</i> , 2011, 258, 704-705.	1.8	1
86	Role of <i>hnRNP-A1</i> and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. <i>Rejuvenation Research</i> , 2011, 14, 275-281.	0.9	57
87	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. <i>Genes and Immunity</i> , 2010, 11, 497-503.	2.2	17
88	Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. <i>Neuroscience Letters</i> , 2010, 469, 234-236.	1.0	24
89	Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. <i>Neuroscience Letters</i> , 2010, 482, 240-244.	1.0	9
90	Teaching Neuroimage: Crowned Dens Syndrome, an Acute Attack of Calcium Pyrophosphate Deposition Disease Mimicking Acute Meningitis. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000200949.	1.5	0